Mineralys Therapeutics, Inc.

NASDAQ: MLYS · Healthcare · Biotechnology

PublicHQ Radnor, PACIK 0001933414Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 61DQ —GM —SS 49

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$154.7M

Employees

Market cap

$1.8B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$154.7M-$154.7M2025

Operating income-$170.6M-$170.6M2025

Total assets$661.8M$661.8M2025

Equity$646.7M$646.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Mineralys Therapeutics, Inc. earned -$154.7M in FY2025 net income.

Peers · Healthcare

Bausch Health Companies Inc.82B+Damora Therapeutics, Inc.——Tyra Biosciences, Inc.——Agilon Health, Inc.56C

Key facts

CEOJon Congleton

SectorHealthcare

IndustryBiotechnology

HeadquartersRadnor, PA

ExchangeNASDAQ: MLYS

Employees51

IPO date2023-02-10

Latest filings

8-K2026-06-03 8-K2026-06-03 8-K2026-05-22 10-Q2026-05-06 8-K2026-05-06 DEF 14A2026-04-08 8-K2026-03-12 10-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.